cabazitaxel + docetaxel + mitoxantrone + satraplatin

This entry describes a hypothetical combination of four distinct antineoplastic agents: cabazitaxel, docetaxel, mitoxantrone, and satraplatin. Cabazitaxel and docetaxel are taxane derivatives that function as microtubule inhibitors, stabilizing microtubules and preventing their disassembly, thereby arresting cell division and inducing apoptosis. Mitoxantrone is an anthracenedione that acts as a type II topoisomerase inhibitor, intercalating into DNA, disrupting DNA synthesis and repair, and causing DNA strand breaks and cross-links. It also exhibits immunomodulatory effects by suppressing immune cell proliferation and function. Satraplatin is an orally active platinum-based compound that forms DNA adducts and cross-links, inhibiting DNA replication and transcription, and leading to cell cycle arrest and apoptosis. While each drug is used individually or in other combinations for various cancers, including prostate, breast, lung, and hematologic malignancies, and mitoxantrone also for multiple sclerosis, this specific four-drug combination is not a recognized therapeutic regimen.

Brand names

JevtanaTaxotere

Other names

cabazitaxel, docetaxel, mitoxantrone, satraplatin